Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes

  title={Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes},
  author={Rury R. Holman and Harald Sourij and Robert M. Califf},
  journal={The Lancet},

Tables from this paper

Cardiovascular outcome trials of glucose‐lowering drugs in type 2 diabetes: 10 frequently asked questions

The cumulative number of patients enrolled in CVOTs over time, and the clear impact of the 2008 FDA/EMA guidance, which was triggered by controversies around the CV safety of rosiglitazone are shown.

[Cardiovascular aspects of diabetes treatment : Finally a reason for cardiologists to be pleased].

Treatment with the SGLT-2 inhibitor empagliflozin and the long-acting GLP-1 receptor agonist liraglutide even significantly improved cardiovascular outcomes in patients with type 2 diabetes mellitus.

A review of cardiovascular outcome trials in type 2 diabetes.

A critical look at CVOTs involving patients with type 2 diabetes focusing on a variety of antihyper-glycaemic drugs, including incretin-based agents, sodium-glucose cotransporter 2 inhibitor (SGLT-2) inhibitors, and insulin formulations is taken.

Heart failure outcomes in patients with type 2 diabetes mellitus: findings from the cardiovascular outcome trials of antidiabetes agents

  • S. Anker
  • Medicine, Biology
    Diabetes mellitus
  • 2020
Ongoing trials such as EMPEROR programme and DAPA-HF in large patient populations with chronic HF could potentially broaden the use of these drugs beyond their conventional therapeutic indication.

Cardiovascular Outcome Trials of Diabetes and Obesity Drugs: Implications for Conditional Approval and Early Phase Clinical Development

In this modern era of metabolic drug development cardiovascular effects of new drug candidates can and should be more rigorously assessed during the early phases of development, to inform go-/no-go decisions.

Comparison of Clinical Outcomes and Adverse Events Associated With Glucose-Lowering Drugs in Patients With Type 2 Diabetes: A Meta-analysis.

Findings are consistent with American Diabetes Association recommendations for using metformin monotherapy as initial treatment for patients with type 2 diabetes and selection of additional therapies based on patient-specific considerations.



Effects of intensive glucose lowering in type 2 diabetes.

The use of intensive therapy to target normal glycated hemoglobin levels for 3.5 years increased mortality and did not significantly reduce major cardiovascular events and identify a previously unrecognized harm of intensive glucose lowering in high-risk patients with type 2 diabetes.

Basal insulin and cardiovascular and other outcomes in dysglycemia.

Although it reduced new-onset diabetes, insulin glargine also increased hypoglycemia and modestly increased weight and had a neutral effect on cardiovascular outcomes and cancers.

Effects of Prandial Versus Fasting Glycemia on Cardiovascular Outcomes in Type 2 Diabetes: The HEART2D trial

Treating diabetic survivors of AMI with prandial versus basal strategies achieved differences in fastingBlood glucose, less-than-expected differences in postprandial blood glucose, similar levels of A1C, and no difference in risk for future cardiovascular event rates.

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.

The effects of intensive blood-glucose control with either sulphonylurea or insulin and conventional treatment on the risk of microvascular and macrovascular complications in patients with type 2 diabetes in a randomised controlled trial were compared.

Safety and Tolerability of Pioglitazone in High-Risk Patients with Type 2 Diabetes

The results suggest that any beneficial effects of pioglitazone on macrovascular outcomes are accompanied by good long-term tolerability in this population of very high-risk patients with type 2 diabetes and established CVD.

Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.

A strategy of intensive glucose control, involving gliclazide (modified release) and other drugs as required, that lowered the glycated hemoglobin value to 6.5% yielded a 10% relative reduction in the combined outcome of major macrovascular and microvascular events, primarily as a consequence of a 21%relative reduction in nephropathy.

The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study

Symptomatic, severe hypoglycaemia was associated with an increased risk of death within each study arm, however, among participants who experienced at least one episode of hypglycaemia, the risk ofdeath was lower in such participants in the intensive arm than in the standard arm.

Does hypoglycaemia increase the risk of cardiovascular events? A report from the ORIGIN trial.

Although allocation to insulin glargine vs. standard care was associated with an increased risk of severe and non-severe hypoglycaemia, the relative risk of CV outcomes with hypglycaemia was lower with insulinglargine-based glucose-lowering therapy than with the standard glycaemic control.

Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes.

An intensive lifestyle intervention focusing on weight loss did not reduce the rate of cardiovascular events in overweight or obese adults with type 2 diabetes.